2020: The Year “The Dumb Money Was The Smart Money”
“The dumb money was the smart money this year,” is how one portfolio manager cited in today’s article sums up the wild swings experienced by…
3 Biotech Stocks With Enormous Catalysts Early In 2021
When it comes to stocks with the potential to make big moves in the first quarter of 2021, the author of today’s article advises that…
Top Biotech Picks For 2021 With The Most Upside Potential
In a new research report, Stifel identifies its 2021 picks from the biotech sector – and today’s article highlights the five Buy-rated stocks from that…
4 Under-$10 Biotech Stocks With Solid Upside Potential For Aggressive Traders
“Many investors, especially more aggressive traders, look at lower-priced stocks as a way to not only make some good money but to get a higher…
With A Focus On Genomics, This Lesser-Known ETF Is Outperforming – And Now May Be The Time To Buy
The lesser-known ETF discussed in today’s article is already beating the market – up 185% year to date – and the author believes it will…
Treating Severe COVID-19 Could Be Just “The Tip Of The Iceberg” For This Biotech Up 38,000%
The small Swiss biotech firm featured in today’s article has been developing a drug that could help patients suffering from severe COVID-19 – and with…
Battle Of The “Strong Buy” Biotechs
BioXcel Therapeutics is a clinical-stage biopharmaceutical company that utilizes artificial intelligence to identify improved therapies in neuroscience and immuno-oncology. TG Therapeutics is a biopharmaceutical company…
3 Biotech Stocks Flying High In The Mid-Cap “Sweet Spot”
In regards to biotech’s bullish year, the author of today’s article notes that “The COVID-19 pandemic has put a fire under many lesser-known names, including…
Biotech Winners And Losers Out Of ASH
A slew of biotech companies studying blood disease treatments presented data this past weekend at the annual American Society of Hematology (ASH) meeting – and,…
High Growth And Reasonable Risk: 2 Biotech Stocks To Consider
“In such a volatile market, it is quite difficult to find reasonably safe and high-growth biotech stocks,” acknowledges the author of today’s article. Of course,…